ChitogenX Inc. Stock

Equities

CHGX

CA1699161032

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 09:30:00 2024-04-23 am EDT 5-day change 1st Jan Change
0.065 CAD 0.00% Intraday chart for ChitogenX Inc. +62.50% 0.00%
Sales 2022 - Sales 2023 - Capitalization 13.27M 18.13M
Net income 2022 -4M -5.46M Net income 2023 -6M -8.2M EV / Sales 2022 -
Net Debt 2022 5.4M 7.37M Net Debt 2023 6.21M 8.48M EV / Sales 2023 -
P/E ratio 2022
-2.45 x
P/E ratio 2023
-2.01 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 73.75%
More Fundamentals * Assessed data
Dynamic Chart
1 week+62.50%
3 months-31.58%
6 months-27.78%
More quotes
1 week
0.07
Extreme 0.065
0.07
1 month
0.04
Extreme 0.04
0.07
Current year
0.03
Extreme 0.03
0.10
1 year
0.03
Extreme 0.03
0.18
3 years
0.03
Extreme 0.03
0.63
5 years
0.03
Extreme 0.03
0.99
10 years
0.03
Extreme 0.03
1.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 19-06-18
Director of Finance/CFO 60 18-09-17
Chief Tech/Sci/R&D Officer - 20-10-31
Members of the board TitleAgeSince
Chief Executive Officer 63 19-06-18
Director/Board Member 65 15-02-04
Director/Board Member 62 21-06-13
More insiders
Date Price Change Volume
24-04-23 0.065 0.00% 4,000

Delayed Quote Canadian Securities Exchange, April 23, 2024 at 09:30 am EDT

More quotes
ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Company’s proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.
More about the company